CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

Theoretically, small molecule CDK4/6 inhibitors (CDK4/6is) represent a logical therapeutic option in non-small cell lung cancers since most of these malignancies have wildtype RB, the key target of CDKs and master regulator of the cell cycle. Unfortunately, CDK4/6is are found to have limited clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Gabriela M., Gimbrone, Nick T., Sarcar, Bhaswati, Percy, Trent R., Gordián, Edna R., Kinose, Fumi, Sumi, Natália J., Rix, Uwe, Cress, W. Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211232/
https://www.ncbi.nlm.nih.gov/pubmed/34138895
http://dx.doi.org/10.1371/journal.pone.0252927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211232/
https://www.ncbi.nlm.nih.gov/pubmed/34138895
http://dx.doi.org/10.1371/journal.pone.0252927

Ejemplares similares